These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1815764)

  • 21. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.
    Freedman RR; Girgis R; Mayes MD
    J Rheumatol; 1999 Nov; 26(11):2386-8. PubMed ID: 10555897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of beraprost sodium on the Raynaud's phenomenon].
    Hiida M; Ushiyama O; Suzuki N; Ohta A; Nagasawa K; Yamaguchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Jun; 19(3):193-200. PubMed ID: 8810544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud's phenomenon.
    Singh S; De Trafford JC; Baskerville PA; Martin JF
    Eur J Clin Invest; 1995 Mar; 25(3):182-5. PubMed ID: 7781665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of Raynaud's disease.
    Cooke JP; Marshall JM
    Vasc Med; 2005 Nov; 10(4):293-307. PubMed ID: 16444858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive investigation of endothelium-dependent dilatation of the brachial artery in women with primary Raynaud's phenomenon.
    Ringqvist A; Jonason T; Leppert J; Ringqvist I
    Clin Sci (Lond); 1998 Mar; 94(3):239-43. PubMed ID: 9616257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular responses to histamine at low temperatures in normal digital skin and Raynaud's phenomenon.
    Bunker CB; Foreman JC; Dowd PM
    Agents Actions; 1991 May; 33(1-2):197-9. PubMed ID: 1716828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
    Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis.
    Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papazoglou S; Papamichael C; Moulopoulou D; Kostamis P; Stamatelopoulos S; Moulopoulos S
    Clin Exp Rheumatol; 1998; 16(2):135-40. PubMed ID: 9536388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Reduced endothelial function is hardly a cause of primary Raynaud's phenomenon. Alternative mechanisms should be studied to clarify the causes].
    Hedenstierna G
    Lakartidningen; 2000 Feb; 97(8):812-3. PubMed ID: 10741019
    [No Abstract]   [Full Text] [Related]  

  • 37. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects.
    Wollersheim H; Thien T; van 't Laar A
    J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis.
    Goodfield MJ; Rowell NR
    Br J Dermatol; 1988 Nov; 119(5):643-6. PubMed ID: 3207617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.